Daily Stock List
Plastic2Oil, Inc. (PTOI)
OTC Markets Group reported previously on Plastic2Oil, Inc. (PTOI), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Plastic2Oil, Inc. is a North American fuel company based in Niagara Falls, New York. The Company formerly went by the name JBI, Inc. It changed its name to Plastic2Oil, Inc. in August 2014. A clean energy enterprise, Plastic2Oil provides technology to recycle waste plastic into liquid fuels, and dirty fuel into clean diesel. Its technology can deliver economic and environmental benefits through replacing refined fuels and diverting waste plastic from landfills. Plastic2Oil transforms unsorted, unwashed waste plastic into ultra-clean, ultra-low sulphur fuel without the necessity for refinement.
Plastic2Oil’s patent-pending Plastic2Oil® (P2O®) process is a commercially viable, scalable proprietary process. The design of it is to provide quick economic benefit for industry, communities, and government organizations with waste plastic recycling challenges. In addition, the Company’s commitment is to the creation of green employment opportunities and a reduction in the cost of plastic recycling programs for municipalities and businesses.
As regards plastic feedstock supply, Plastic2Oil’s feedstock sources primarily include post-commercial and industrial waste plastic. The P2O processor accepts unwashed, unsorted waste plastic, composites and commingled materials that are difficult to dispose of and are typically found in industrial waste streams. Plastic2Oil believes its P2O process provides a cost-effective, environmental solution for communities and businesses.
Plastic2Oil is partnering with businesses and municipalities that collect waste plastics. This waste plastic is normally delivered to independent Material Recycling Facilities (MRFs), where it is frequently sent to landfills. The Company’s objective is to help redirect these waste plastic streams, preventing them from entering local landfills.
Plastic2Oil is negotiating a strategic partnership. In August 2016, the Company announced the signing of a Memorandum of Understanding (MOU) with a potential partner concerning the licensing of Plastic2Oil’s technology and a potential sale of processor units.
The Company is still in the process of negotiating a definitive agreement with the potential partner. If consummated, the anticipation is that the initial site would house two Plastic2Oil processors, and eventually may lead to deployment of processors in 15 to 20 similar facilities.
Plastic2Oil, Inc. (PTOI), closed Friday's trading session at $0.05, up 11.23%, on 69,072 volume with 8 trades. The average volume for the last 60 days is 46,029 and the stock's 52-week low/high is $0.018/$0.07.
Echo Therapeutics, Inc. (ECTE)
StreetInsider, StockOodles, MarketWatch, TopPennyStockMovers, Wall Street Resources, SmarTrend Newsletters, The Street, Penny Stock Rumble, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, Greenbackers, PennyOmega, PennyToBuck, StockHotTips, and AllPennyStocks reported on Echo Therapeutics, Inc. (ECTE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Echo Therapeutics, Inc. is a medical device company with its corporate headquarters in Iselin, New Jersey. The Company’s emphasis is on non-invasive continuous glucose monitoring (CGM) and associated technologies. It is developing its non-invasive, wireless, CGM system. The Company has successfully demonstrated the ability to continuously monitor blood glucose non-invasively in healthy, Type I, Type II, and hospital patients. Individuals’ glucose data can be displayed on any mobile platform. The glucose data can also be accessed from the cloud for remote monitoring.
Echo Therapeutics became a public company on September 14, 2007 due to the merger of Sontra Medical Corp. and then privately held Echo Therapeutics, Inc. After this merger, Sontra Medical changed its name to Echo Therapeutics, Inc. on October 8, 2007. Echo Therapeutics’ shares trade on the OTC Markets Group’s OTCQB.
Echo Therapeutics says that a significant opportunity exists for its CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. Furthermore, it says that a longer-term opportunity exists in hospital settings.
The Company has developed its needle-free skin preparation device as a platform technology, which allows for enhanced skin permeation enabling extraction of analytes, including glucose, and enhanced delivery of topical pharmaceuticals. Its precise exfoliator is an innovation in personal monitoring technology. The proprietary skin preparation device painlessly exfoliates an exact portion of the outer layer of dead skin. This is for optimal glucose and analyte extraction.
Echo Therapeutics has received Institutional Review Board (IRB) approval for a new clinical protocol. The new protocol permits expanded testing of Echo's CGM system. In addition, it allows the Company to recruit pediatric and adult subjects for its internal and external studies.
Furthermore, Echo Therapeutics is actively seeking partnerships with industry leaders in wearable technology, medical devices, big data, and pharmaceutical drug delivery. The Company’s partnerships include MTIA (a China healthcare leader); and Handok (Korea’s leader in diabetes treatment).
Echo Therapeutics, Inc. (ECTE), closed Friday's trading session at $0.16, even for the day, on 13,950 volume with 2 trades. The average volume for the last 60 days is 36,224 and the stock's 52-week low/high is $0.08/$2.8399.
Soupman, Inc. (SOUP)
DreamTeamNetwork, The Wall Street Transcript, TopPennyStockMovers, Stock Guru, The Street, FeedBlitz, Street Beat, and Pumps and Dumps reported on Soupman, Inc. (SOUP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Soupman, Inc. sells soup across the United States in Tetra Pak cartons. The Company sells in grocery stores and also in its franchise restaurants, soupmobiles and foodservices. The Original SoupMan® opened its doors in 1984 at 55th Street & 8th Avenue in Manhattan. Soupman has its head office in Staten Island, New York.
Soupman added two new flavors to its lineup last year. These are Shrimp Bisque and Turkey Stew. The Company has a number of varieties of Soupman soup that are available in supermarkets across the nation. The other varieties available in Tetra Pak cartons include Lobster Bisque, Gluten-Free Lentil, Jambalaya, Crab & Corn Chowder, Chicken Gumbo, and Chicken Noodle.
All Soupman soups are packaged in environmentally friendly, "green" Tetra Pak cartons. These cartons are shelf stable. The design of them is to keep product flavor first-rate without preservatives.
In addition, Soupman soups are available in the soup aisle of grocers and supermarkets nationally. These include Publix, Kroger, Ralph's, Vons, Pavilions, HEB, Shoprite, Wegman's, and Safeway, as well as other retailers.
In November 2016, Soupman announced it is partnering with Mr. George Naddaff, the founder of Boston Market, to bring Soupman soups to strategic restaurant partners and other food service venues throughout the country. Mr. Naddaff is the Chairman and Chief Executive Officer of Business Expansion Consulting Company, a Boston-based M & A advisory and consulting enterprise that concentrates on expanding growth brands with its wide-ranging contacts and experiences in the restaurant industry.
In the Q1 2017 fiscal quarter ended November 30, 2016, Soupman total revenue for the quarter was $1.050 million. The Company’s Tetra Pak sales grew 121 percent over Tetra Pak sales in comparison to Q1 2016 on top of the 92 percent Tetra Pak sales increase for the fiscal year ending August 31, 2016 over the prior year. This is the fourth consecutive quarter of Tetra Pak sales increases.
Soupman’s work over the past year was geared to building Tetra Pak sales through building points of distribution. At present, the Company has around 6,500 points of distribution. Therefore, its work will now center on building sales in these existing stores.
Soupman, Inc. (SOUP), closed Friday's trading session at $0.0163, up 15.60%, on 573,783 volume with 18 trades. The average volume for the last 60 days is 175,113 and the stock's 52-week low/high is $0.01/$0.0899.
NEXT Group Holdings, Inc. (NXGH)
RedChip, BUYINS.NET, StockEgg, Penny Invest, and OTC Picks reported on NEXT Group Holdings, Inc. (NXGH), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
NEXT Group Holdings, Inc., by way of its operating subsidiaries, engages in the business of using proprietary technology and certain licensed technology to provide inventive mobile banking, mobility, and telecommunications solutions to underserved, unbanked, and emerging markets. NEXT Group Holdings owns 94 percent of the issued and outstanding shares of NEXTCALA, which is one of the Company’s four operating subsidiaries. NEXT Group Holdings is based in Miami, Florida.
The Company maintains a technology portfolio encompassing several verticals. Its subsidiaries are NEXT|CALA, a general purpose reloadable Visa Card; NXT|GN, a provider of a multipoint HD video platform; and NEXT|MOBILE360, a provider of mobile voice, text, and data services.
NEXT|CALA is the Company’s flagship product. NEXTCALA powers its mobile banking solution and reward program(s). The card is a safe and cost-effective substitute to carrying cash. NEXTCALA cards are acceptable wherever Visa debit cards are accepted. NEXTCALA cards can be used for all transactions.
NEXT Group Holdings’ NXT|GN business unit, in cooperation with Cisco Systems, developed in 2012 an innovative product called AVYDA powered by Telarix. This is an HD telepresence platform. It enables millions of people to connect using their mobile phones, tablets and PCs into celebrities, talents, healthcare and education applications on Android and iOS operating systems. AVYDA permits HD video conferences to connect point-to-multipoint.
Next Group Holdings has completed the acquisition of Tel3. With this agreement, it acquired the telecom marketing brand "Tel3" together with the assets and client database of Tel3. Tel3 is a marketing group.
Next Group Holdings announced in August 2015 that it signed a definitive Agreement with InsightPOS, LLC, for distribution, market development, and revenue sharing in a new cash register Interactive Point Of Sale (POS) system. InsightPOS is a State of the Art "Super Functional Point Of Sale". Insight POS can replace the entire cash register, inventory and management system.
This past December, Next Group Holdings announced that it amended and extended its White Label Card Program Services agreement with InComm Financial Services, Inc., calling for InComm’s continuing use of NEXT Group’s marks and certain InComm marks in connection with the parties’ prepaid card program. NEXT Group Holdings and InComm have further committed to explore efforts to provide Next CALA customers with an enhanced user experience meeting their changing needs in the contemporary marketplace.
NEXT Group Holdings, Inc. (NXGH), closed Friday's trading session at $0.022, up 7.84%, on 107,937 volume with 12 trades. The average volume for the last 60 days is 241,563 and the stock's 52-week low/high is $0.0096/$0.335.
Atlas Technology International, Inc. (ATLT)
We are reporting on Atlas Technology International, Inc. (ATLT) today, here at the QualityStocks Daily Newsletter.
Atlas Technology International, Inc. is a designer, manufacturer and distributor of touchscreen devices. The Company provides these to consumer electronic producers globally. Atlas is a worldwide leader in the design and distribution of touchscreen devices.
The Company has pioneered new interfaces for GPS systems, Point of Sale (POS) machines, Hospitality, Medical and Small Appliances. Atlas Technology International has its corporate headquarters in Sherman Oaks, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.
Pertaining to touchscreens, the Company’s team is centering on better, smarter materials, easier integrations into any device, as well as attaining new technological breakthroughs. Its full-service design team takes projects from concept through prototype, testing, production and beyond. The Company has the ability to deliver the design and product manufacturing backed by its advanced research and development (R&D).
Regarding manufacturing, Atlas Technology International is a one-stop shop for its customers. The Company handles all facets of product creation. Atlas’ addressable market is consumer product groups, car manufacturers, and finance and insurance.
Last month, Atlas Technology International reported financial results for its fiscal 2017 Q2 and first half ended December 31, 2016. The Company’s revenues increased to $769,821 in its first full core-business operating quarter. Atlas posted $1,005,792 in revenues for its first half of Fiscal Year 2017 ended December 31, 2016, a period consisting of 19 weeks of operations.
Mr. Matthew Tsai, Chief Executive Officer, commented on Atlas Technology International’s first full quarter as a publicly traded, touchscreen operating company, “We’re off to an excellent start, and hold high expectations for our performance in the second half of Fiscal Year 2017 ending June 30. In the past few months we have become a public company, built a solid corporate infrastructure and quickly ramped up customer orders, revenue and posted a modest profit for what we consider effectively breakeven net income.”
Atlas Technology International, Inc. (ATLT), closed Friday's trading session at $0.30, up 20.00%, on 16,142 volume with 9 trades. The average volume for the last 60 days is 6,214 and the stock's 52-week low/high is $0.21/$4.00.
InMed Pharmaceuticals, Inc. (IMLFF)
The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.271, up 1.08%, on 850,954 volume with 290 trades. The stock’s average daily volume over the past 60 days is 798,865, and its 52-week low/high is $0.05/$0.4261.
InMed Pharmaceuticals Inc. yesterday announced the filing of an international Patent Cooperation Treaty (PCT) application, an important component in providing intellectual and commercial protection for INM-750 as a cannabinoid-based topical therapy for Epidermolysis Bullosa Simplex (EBS).
InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.
Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”
After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.
The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.
InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.
The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.
Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.
Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer
InMed Pharmaceuticals, Inc. News:
InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
InMeds Bioinformatics Platform Powers Cannabinoid Drug Development -- CFN Media
InMed Receives over $1,350,000 From Warrant Exercise
GreenStone Healthcare Corp. (GRST)
The QualityStocks Daily Newsletter would like to spotlight GreenStone Healthcare Corp. (GRST). Today, GreenStone Healthcare Corp. closed trading at $0.05, up 26.74%, on 260,289 volume with 13 trades. The stock’s average daily volume over the past 60 days is 57,761, and its 52-week low/high is $0.015/$0.083.
GreenStone Healthcare Corp. (GRST), developed and ran a first class addiction treatment center in Muskoka. Ontario. Greenestone recently restructured by selling its Muskoka treatment center business, purchasing the underlying real estate of the treatment center and leasing it to the purchasers. It also purchased a treatment center business and real estate in Delray Beach, Florida. GreenStone will not compete in the Canadian marketplace and focus on the much larger US market for addiction treatment. Greenestone is uniquely qualified to bring its well honed practices to the US marketplace and can thrive in the current challenging environment of substance addictions.
GreeneStone employs the best principles and practices currently available in the treatment of individuals with addiction. To ensure the most comprehensive and effective treatment for its clients, GreenStone treats underlying or co-occurring disorders in tandem with the treatment of addiction.
The 36-bed addiction treatment center offers a holistic, individualized treatment approach to recovery. These private, paid programs vary in length from 45-90 days, depending on the unique needs of each resident and their response to the treatment.
GreenStone also provides education and counseling sessions to educate the family members of its residents with the objective of helping them better understand the disease of addiction and how they should support their loved one throughout and after their recovery efforts.
GreenStone Healthcare President Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries, including industrial minerals, aggregates, oil and gas, mining, financial, technology, hospitality and medical. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. He is joined by Vice President Dr. Anita Teslak, whose 25 years of combined experience as a CEO, psychologist and leadership provides valuable insight into a successful business model. Disclaimer
GreenStone Healthcare Corp. Company Blog
GreenStone Healthcare Corp. News:
GreeneStone Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
GreeneStone Signs Definitive Agreement to Acquire Seastone of Delray, a Florida Limited Liability Company
GreeneStone Signs LOI to Acquire Aurora Recovery
Stealth Technologies Inc. (STTH)
The QualityStocks Daily Newsletter would like to spotlight Stealth Technologies Inc. (STTH). Today, Stealth Technologies Inc. closed trading at $0.02731, up 9.24%, on 25,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 27,968, and its 52-week low/high is $0.015/$0.05.
Founded in 1999, Stealth Technologies Inc. (STTH) is focused on developing and marketing products that deliver cost effective, independently validated solutions for large addressable international and domestic markets. The company's primary target is identity protection and personal safety.
The Stealth Card represents the company's flagship solution for identity protection. Today there are more than 1.5 billion credit and debit cards in circulation with RFID chips, making it easier than ever for identity thieves to steal sensitive information without contact. The paper-thin Stealth Card offered by Stealth Technologies protects up to 12 RFID credit cards in a wallet without any batteries or charging requirements.
StealthIdentityTheft.com is an expansion of the company's commitment to provide first-rate identity protection solutions. The proprietary system underlying this identity protection and recovery service was designed in partnership with law enforcement officials. Utilizing the most effective methods of prevention involving a two-step process, StealthIdentityTheft.com is a superior answer to the non-stop identity theft taking place every day.
The international marketplace was infiltrated by Stealth Technologies when the company launched its 911 HELP NOW™ emergency medical alert device. Providing direct access with 911 service at a touch of a button, the device is packed with powerful features including a full year of battery life from standard AAA batteries, compact ergonomic design, 2-way voice and a durable, splash resistant design.
Stealth Mobile is the latest product offering introduced to leverage the Stealth Technologies' brand and sales channels established by the other products. Similar to the Stealth Card, Stealth Mobile prevents electronic pickpocketing. The product guards NFC transmissions emitted by cell phone devices, which can include personal information, messages and financial data.
Stealth Technologies recognizes the value of the rapid sales growth generated by these technologies and has multiple patents pending to safeguard its investments. With an expanding product suite and ongoing expansion into the identity theft protection marketplace, Stealth Technologies remains committed to its focus on increased growth and profitability. Disclaimer
Stealth Technologies Inc. Company Blog
Stealth Technologies Inc. News:
Stealth Technologies Announces 5 New Products
Stealth Technologies Highlights Opportunities from Attendance at Leading Real Estate, Home Staging Conference
NetworkNewsWire Releases Exclusive Audio Interview with Stealth Technologies, Inc. (STTH)
ORHub, Inc. (ORHB)
The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.70, even for the day, on 268,270 volume with 103 trades. The stock’s average daily volume over the past 60 days is 31,615 and its 52-week low/high is $0.05/$2.09.
ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.
The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.
Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.
Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.
In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.
ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.
The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.
ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.
Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer
ORHub, Inc. Blog
ORHub, Inc. News:
ORhub, Inc. (ORHB) Engages NetworkNewsWire for Corporate Communications Solutions
ORHub, Inc. (ORHB) Expands Operations at Nation's Second Largest Non-Profit Hospital System
ORHub, Inc. (ORHB) Featured in NetworkNewsWire's NetworkNewsBreaks, Top 10 Mid-day Percentage Gainers, Feb 14
National Waste Management Holdings, Inc. (NWMH)
The QualityStocks Daily Newsletter would like to spotlight National Waste Management Holdings, Inc. (NWMH). Today, National Waste Management Holdings, Inc. closed trading at $0.09, off by 0.33%, on 42,567 volume with 7 trades. The stock’s average daily volume over the past 60 days is 25,989, and its 52-week low/high is $0.06/$0.5622.
National Waste Management Holdings, Inc. (NWMH) is a solid waste management company offering comprehensive solutions for full waste diversion along Florida's west coast and in upstate New York. With an established base of long-term partnerships with municipal, institutional, commercial and industrial customers, along with a successful acquisition strategy, National Waste has set its course to become a leading waste diversion company.
National Waste's 54-acre landfill facility located in Hernando, Florida, handles annual average disposals of roughly 240,000 cubic yards of construction debris annually. The site also offers an array of ancillary services such as roll-off dumpster services, mulching services and recycling. While the landfill facility is already permitted for future expansion, National Waste's growth strategy also calls for the opening of new satellite offices in counties and states that neighbor its existing operations.
In addition to increasing its geographic foothold, National Waste employs a strategic acquisition model to increase its overall market share. In 2015, the company acquired Gateway Rolloff Services LP and Waste Recovery Enterprises LLC, which are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward. In the second quarter of 2016, National Waste added Sivart Services to its roster, creating an immediate source of additional revenue and expanding its foothold in the northeast area of New York.
Management has confirmed its interest in additional acquisition targets while demonstrating its ability to effectively integrate and organically grow the company's existing acquisition companies and maintain efficient operations. Disclaimer
National Waste Management Holdings, Inc. Company Blog
National Waste Management Holdings, Inc. News:
National Waste Management Holdings, Inc. Expands Territory with Acquisition of Burts Refuse, LLC
National Waste Management Holdings, Inc. (NWMH) Expands Market Reach in New York with Acquisition of Northeast Data Destruction and Recycling
National Waste Management Holdings, Inc. Ends Year on High Note, Announces Final Acquisition of 2016
Today's Top 3
Penny Stock Prodigy
Trader Power News
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- ChineseInvestors.com, Inc. (CIIX) to Present at the National Investment Banking Association Conference in New York City on February 28, 2017
- Dominovas Energy Corp. (DNRG) Enters Formal Negotiations to Open in India and Indonesia
- eXp World Holdings, Inc. (EXPI) to Present at Annual ROTH Conference
- GreenStone Healthcare Corp. (GRST) Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
- InMed Pharmaceuticals Inc. (IMLFF) InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
- Monaker Group, Inc. (MKGI) to Present at the 29th Annual ROTH Conference, March 15, 2017
- National Waste Management Holdings, Inc. (NWMH) Expands Territory with Acquisition of Burts Refuse, LLC
- ORHub, Inc. (ORHB) Engages NetworkNewsWire for Corporate Communications Solutions
- Players Network (OTCQB: PNTV) Featured on MoneyTV with Donald Baillargeon, 2/17
- Singlepoint, Inc. (SING) Takes a Low Risk Approach to the Cannabis Industry -- CFN Media
- Stealth Technologies, Inc. (STTH) Announces 5 New Products